Propanc Biopharma, Inc. is facing the possibility of being delisted from The Nasdaq Stock Market after receiving a notice of non-compliance with the minimum bid price requirement. This situation is significant as it reflects ongoing challenges for smaller pharmaceutical companies in maintaining their market presence.

On October 23, 2026, Propanc Biopharma received a written notice from Nasdaq indicating that its common stock did not meet the $1.00 minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2). The company’s stock price had fallen below this threshold for 30 consecutive business days prior to October 21, 2026. Typically, companies are granted a 180-day compliance period to rectify such issues. However, Propanc is ineligible for this grace period due to a previous reverse stock split.

The notice states that Propanc’s securities will be delisted on November 2, 2026, unless the company appeals this determination by October 30, 2026. Propanc intends to request an appeal, believing it has addressed the bid price deficiency since receiving the notice.

Founded in Delaware and operating under the SIC code 2834, which pertains to pharmaceutical preparations, Propanc Biopharma focuses on developing treatments for cancer and other serious diseases. The company trades under the ticker PPCB on the Nasdaq exchange.

The filing reveals that the company’s receipt of the notice does not impact its business operations or reporting requirements with the SEC. However, a delisting could have severe consequences, including reduced liquidity and market price for its stock, diminished investor interest, and challenges in raising equity financing. The company also noted that delisting could impair its ability to offer equity incentives to employees.

As for the next steps, Propanc Biopharma is set to file an appeal with Nasdaq by the specified deadline. If successful, this could allow the company to remain listed and potentially recover from its current challenges.

In conclusion, the situation underscores the volatility faced by smaller companies in the pharmaceutical sector, particularly regarding compliance with exchange listing standards. Propanc’s efforts to appeal the delisting decision will be closely monitored by investors and industry observers alike.